Microfluidic Device Systems Market in North America to Grow at Striking 21.70% CAGR from 2013 to 2019

There has been a recent release of a new report on the global microfluidic device systems market by Transparency Market Research (TMR). The report suggests that the global microfluidic device market is estimated to grow at a CAGR of 22.8% during the period of 2013 to 2019. The market, which was valued at US$1.5 bn in 2013, will reach US$5.2 bn in 2019.The report, which is titled “Microfluidic Device System Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019,” provides a comprehensive study on the analysis of the microfluidic device market for the period from 2014 to 2019, wherein 2013 is considered as the base year for calculation. The report contains data related to the current market dynamics, trends, market drivers, restraints, and also the strategic developments propelling the global microfluidic device systems market.

The report states that the rising demand for microfluidic devices in proteomics and genomics, point of care testing, and miniaturization of chips are the chief driving forces behind the microfluidic device systems market’s growth. Another factor that could fuel the growth of the microfluidic device systems market is a change in the material mix, which would provide an opportunity to new market entrants. Conversely, strict regulations and standards for global affiliation of medical devices as well as high performance and consistency in quality of the devices are some of the factors limiting the growth of the microfluidic device systems market. Manufacturing issues such as surface chemistry and geometrical issues also account for the challenges faced by the microfluidic device systems market.

The report categorizes the global market for microfluidic device systems chiefly on the basis of four criteria: geography, industry, application, and materials used in the manufacturing process of microfluidic devices.

On the basis of application, the market for microfluidic devices is segmented into pharmaceutical and life sciences research, point of care testing, environment and industrial, clinical and veterinary diagnostics, and drug delivery. Of these, the largest segment of the microfluidic devices market is the veterinary and clinical diagnostic application segment.

Geographically, the microfluidic devices market is segmented into Asia, North America and Europe, wherein North America dominates the global microfluidic devices market, while Asia is a rapidly developing region for the microfluidic devices market.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1561

On the basis of industry, the microfluidic devices market is segmented into in- vitro diagnostics, pharmaceuticals, and medical devices. Among these, in-vitro diagnostics is the largest industry and is estimated to reach US$3.3 bn in 2019.

The report profiles some of the prominent companies such as Abbott Laboratories, Roche Diagnostics, Siemens Healthcare, Becton Dickinson and Company, Agilent Technologies, Fluidigm Corporation, Bio-Rad Laboratories, and Johnson & Johnson, which are key players in the microfluidic devices market.

The market for microfluidics devices can be expected to rise as microfluidics is an evolving field with a huge potential commercially. With applications in various fields such as cell biology research, protein crystallization, and medicine, microfluidics will remain in the market due to its efficacy in the field of treatment.

India Leads Global Medical Tourism Industry thanks to Presence of Advanced Medical Technologies

The global medical tourism market is led by some of the key companies including Apollo Hospitals (India), Prince Court Medical Center, and Bumrungrad International Hospital (Thailand). Key companies are concentrating on sophisticating some of the medical tourism services including neurosurgery, cardiac surgery, dental care, cosmetic surgeries, and orthopedics. Over the past years, the global medical tourism market has growth at a considerable rate owing to the rising medical infrastructure and the availability of medical devices. Globalization of health care services has largely propelled the global medical tourism market. Transparency Market Research Report (TMR), in its new report, states that changing trends in globalization of the healthcare industry have assisted people to avail affordable medical services.

The global medical tourism market is expected to reach US$32.5 bn by 2019. Based on geography, the global medical tourism market was dominated by India in the recent past and the trend is expected to continue in the years to come. The medical tourism market in India is predicted to reach US$14,058.1 mn by 2019, followed by Brazil. Asia has become the most prominent markets for medical tourism, with countries such as India, Malaysia, Thailand, and Singapore leading the demand for healthcare services. Cultural similarity and geographic proximity are two of the factors that can be credited for the growth of the medical tourism market in Asia.

Aging Population to Propel Global Demand for Medical Tourism

The rising aging population is a boon for the global medical tourism market. With age, people are facing many health issues. The demand for quality medical care and treatment is increasing in many nations. Some other factors expected to boost the demand for medical tourism are the reduced cost of procedures, large uninsured population, the rising tourism industry, and wider treatment options. An improved healthcare infrastructure is benefiting the players operating in the global medical tourism industry to offer required services. Thanks to improved medical infrastructure, aging people are able to avail medical services while being on a tour.

Follow-up Care to be the Biggest Challenge

Although the global demand for medical tourism is increasing at a considerable pace, the lack of follow-up care is expected to be the biggest challenge for the key companies operating in the global medical tourism market. “Management of post-treatment complications and post-operation complications are still a problem for the patients,” says TMR analysts. Local healthcare service providers find it uncomfortable to solve complicated medical cases that are performed by unknown medical professionals in various tourist locations. This is another problem expected to restrict the growth of the global medical tourism market.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=900

Government Support to Create New Opportunities

Governments of many nations are supporting medical tourism by increasing their funding for research and development of new drugs. With favorable government policies, medical tourism has been simplified. Medical tourism has gained significant importance in the global tourism market. Governments of countries such as India, Singapore, Thailand, and China have formed separate medical tourism agencies to be a part of the growing global medical tourism market. Many governments are allowing new companies to enter the global medical tourism market, which is expected to propel the market in many ways.

This information is based on the findings of a report published by Transparency Market Research titled “Medical Tourism Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019.”

The global medical tourism market is segmented as follows:

Medical Tourism Market, by Geography

• India
  • Overview
  • Cost Comparison of Procedures
  • SWOT Analysis
  • Government Support
  • India Inbound Medical Tourism (No. of patients)
  • India Medical Tourism: Top Revenue Contributing Country (%) (2012)
• Thailand
  • Overview
  • Cost Comparison of Procedures
  • SWOT Analysis
  • Government Support
  • Thailand Inbound Medical Tourism ( No. of patients)
  • Thailand Medical Tourism: Top Revenue Contributing Country (%) (2012)
• Singapore
  • Overview
  • Cost Comparison of Procedures
  • SWOT Analysis
  • Government Support
  • Singapore Inbound Medical Tourism ( No. of patients)
  • Singapore Medical Tourism: Top Revenue Contributing Country (%) (2012)
• Malaysia
  • Overview
  • Cost Comparison of Procedures
  • SWOT Analysis
  • Government Support
  • Malaysia Inbound Medical Tourism ( No. of patients)
  • Malaysia Medical Tourism: Top Revenue Contributing Country (%) (2012)
• Mexico
  • Overview
  • Cost Comparison of Procedures
  • SWOT Analysis
  • Government Support
  • Mexico Inbound Medical Tourism ( No. of patients)
  • Mexico Medical Tourism: Top Revenue Contributing Country (%) (2012)
• Brazil
  • Overview
  • Cost Comparison of Procedures
  • SWOT Analysis
  • Government Support
  • Brazil Inbound Medical Tourism ( No. of patients)
  • Brazil Medical Tourism: Top Revenue Contributing Country (%) (2012)
• Turkey
  • Overview
  • Cost Comparison of Procedures
  • SWOT Analysis
  • Government Support
  • Turkey Inbound Medical Tourism ( No. of patients)
  • Turkey Medical Tourism: Top Revenue Contributing Country (%) (2012)
• South Korea
  • Overview
  • Cost Comparison of Procedures
  • SWOT Analysis
  • Government Support
  • South Korea Inbound Medical Tourism ( No. of patients)
  • South Korea Medical Tourism: Top Revenue Contributing Country (%) (2012)
• Taiwan
  • Overview
  • Cost Comparison of Procedures
  • SWOT Analysis
  • Government Support
  • Taiwan Inbound Medical Tourism ( No. of patients)
  • Taiwan Medical Tourism: Top Revenue Contributing Country (%) (2012)
• Prospective Countries
  • Costa Rica
  • Poland
  • Dubai
  • Philippines

Contact us:

Transparency Market Research

90 State Street,

Suite 700,

Albany

NY - 12207

United States

Tel: +1-518-618-1030

USA - Canada Toll Free 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/

Neuromodulation Devices Market - Latest Innovations, Drivers, Restraints, Challenges and Forecast 2012 - 2018

Transparency Market Research, in a report titled “Neuromodulation Devices Market - Global Industry Size, Market Share, Trends, Analysis, And Forecast 2012 - 2018,” states that the global neuromodulation devices market is anticipated to expand at a strong CAGR of 14.40% from 2012 to 2018, rising from an estimated value of US$2.7 bn in 2011 to over US$7 bn by 2018.

Neuromodulation devices are advanced medical devices that suppress or enhance the activity of the nervous system for the effective treatment of a particular disease. Neuromodulation technologies can be both implantable as well as non-implantable and comprise devices that deliver chemical, electrical, or other agents to modify nerve cell and brain activity.

The global neuromodulation devices market is driven by a number of factors, including major technological advancements, the add-on therapy nature of neuromodulation devices, the surge in healthcare expenditure by consumers, the rising prevalence of lifestyle-associated disorders such as obesity and depression, the increasing prevalence of diseases such as Alzheimer’s and Parkinson’s, the rising incidence of chronic diseases, the surge in unmet medical needs, the growing demand for minimally invasive surgeries, and the increase in external funding for clinical studies. In contrast, strict FDA approval norms and other government restrictions, the risks and side effects associated with the use of neuromodulation devices, and the availability of alternate treatment options threaten to impede the global neuromodulation devices market.

The report studies the overall market for neuromodulation devices by segmenting it on the basis of type of technology, area of application, and geography.

By type of technology, the neuromodulation devices market is divided into deep brain stimulation, vagus nerve stimulation, spinal cord stimulation, sacral nerve stimulation, and gastric electric stimulation. On the basis of area of application, the neuromodulation devices market is categorized into Boston Scientific’s Precision Spinal Cord Stimulation System, St. Jude Medical’s Eon Mini Neurostimulator System, IntraPace’s Abiliti System, Cyberonics’ VNS Therapy System, Medtronic’s Enterra Therapy System, Medtronic’s Spinal Cord and Deep Brain Neurostimulation Systems, Codman & Shurtleff’s Medstream System, and Nevro’s Senza System for Spinal Cord Stimulation.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=627

The global neuromodulation devices market is geographically divided into Asia Pacific, Europe, North America, and Rest of the World. Accounting for a massive 65.0% share in the overall market, North America emerged as the leader in the neuromodulation devices market in 2011 and was valued at US$1.7 bn. There has been a considerable rise in the demand for neuromodulation devices in the developing economies in Asia Pacific and this surge in demand is anticipated to drive the Asia Pacific neuromodulation devices market at a remarkable CAGR of over 15.0% from 2012 to 2018. A number of emerging economies in Eastern Europe and Latin America are also anticipated to gain prominence in the neuromodulation devices market over the coming years.

The report identifies the leading players operating in the global neuromodulation devices market and reviews them based on attributes such as business strategies, company overview, product portfolio, financial overview, and recent developments. Boston Scientific Group, Nevro, Cervel Neurotech Inc., Codman and Shurtleff, Integra, Uroplasty, IntraPace, Cyberonics, Medtronic, St. Jude Medical, and Neuronetics Inc. are some of the top companies competing in the neuromodulation devices market.

Microfluidic Device Systems Market in North America to Grow at Striking 21.70% CAGR from 2013 to 2019

Transparency Market Research has recently published a new research report that evaluates the overall global microfluidic device systems market and provides a trajectory of the market. The research report, titled “Microfluidic Device System Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019,” studies microfluidic devices system as an evolving scientific field that has myriad analytical applications and a huge commercial potential.

It is a multidisciplinary field that uses engineering, chemistry, physics, nanotechnology, biochemistry, and biotechnology with practical solutions that use low fluid volumes achieve automation, multiplexing, and high-throughput screening. These devices are used in areas of cell biology research, medicine, and protein crystallization. The primary goal of these devices is to bring in efficiency and improve treatments.

According to the research report, the global microfluidic device systems market was valued at US$1.5 bn in 2013 and is expected to reach US$5.2 bn by 2019, rising at a CAGR of 22.80% between 2013 and 2019. The key factor propelling the global microfluidic device systems market is the high demand for these systems in chip miniaturization, proteomics, and genomics. Furthermore, the growing demand from the point-of-care testing segment will also boost this market.

The global microfluidic device systems market has been segmented on the basis of material, industry, application, and geography. The materials available in this market are glass, silicon, and polymer. The industries using these systems are pharmaceuticals, medical devices, and in-vitro diagnostics. On the basis of application this market is segmented into point of care testing, pharmaceutical and life science research, drug delivery, analytical devices, clinical and veterinary diagnostics, and environment and industrial. Geographically, this market is segmented into North America, Europe, Asia Pacific, and Rest of the World.

Of all the industries, the in-vitro diagnostics industry is the largest user of microfluidic device systems. This industrial segment was valued at US$949.6 mn in 2013 and is likely to reach US$3.3 bn in 2019, surging at a CAGR of 23.20% 2013 and 2019. Meanwhile, the medical devices segment will also play a vital role in the changing application dynamics of the global microfluidic device systems market.

Out of all the applications, the veterinary and clinical diagnostics held the largest share in the market. However, analysts predict that point of care testing segment will show a remarkable growth rate in the global microfluidic device systems market in the foreseeable future. The North America microfluidic device system market holds a dominant position as it was valued at US$644.5 mn in 2013 and is expected to reach US$2 bn in 2019, expanding at a CAGR of 21.70% from 2013 to 2019.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1561

Some of the key players in the global microfluidic device systems market are Roche Diagnostics, Siemens Healthcare, Abbott Laboratories, Bio-Rad Laboratories, Agilent Technologies, Fluidigm Corporation, Becton Dickinson and Company, and Johnson & Johnson. The research report profiles these players and provides a complete analysis of the competitive landscape of the overall market. Furthermore, the report also presents a fair case of regulatory framework governing the overall market. The research and development activities, branding ideas, business and marketing strategies, and strategic mergers and acquisitions of these players have also been mentioned in this extensive research report.

Medical Disposables Market: Industry Players Shifting Focus towards Developing Economies

Disposal of medical waste has become a daunting task for healthcare practitioners as the need for sustainable disposal solutions has become a pressing one. This has brought the packaging materials being used for storing medical devices into the spotlight. To reduce the impact of medical wastes on the environment and to minimize the chances of cross-contamination, players operating in the global medical disposables market are focusing on thoughtful product engineering and design. The key players in the global market are Johnson & Johnson, Dickinson, and Company, Becton, 3M Company, and Covidien plc.

Download Free exclusive Sample of this report:

http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=388

Q. What are the recent developments in the global medical disposables market?

A. In June 2016, Husky Injection Molding Systems won the Process Innovation Supplier award from Becton Dickinson. The award was in recognition of the company’s effort towards promoting Becton Dickinson's vision to improve customer satisfaction levels while meeting the needs to develop effective solutions for disposal of medical wastes. Husky’s Medical Business Unit stated that it intends to reduce the amount of waste and the cut down on the capital expenses that are lost in managing the waste materials. The company has also shown a promise of improving productivity and optimizing the floor space.

According to the research report the global medical disposables market is anticipated to be worth US$193.9 bn by the end of 2018 rising from US$144.6 bn in 2011, as the market progresses at a CAGR of 4.30% CAGR between 2012 and 2018.

Q. Why will certain end users benefit during the forecast period?

A. The end users in the global medical disposables market are emergency care units, home healthcare facilities, outpatient facilities, physician offices, and hospitals. Of these, the hospitals are the prime end users due to the growing number of patient admissions, emergency visits, and high frequency of surgical procedures. However, the home healthcare segment is anticipated to be fastest-growing one in the near future as the healthcare sector is focusing on reducing the number of readmissions, hospital stays, and providing preventive medical assistance to the elderly. This trend is predominantly being seen in the U.S.

Q. Which region besides North America will witness a significant growth rate?

A. In terms of geography, the global disposables market is segmented into North America, Europe, Asia Pacific, and Rest of the World. Out of these four regions, the North America medical disposables market is anticipated to soar in the coming years, primarily due to a dependable healthcare infrastructure. According to the extensive research report, North America held a share of about 70% in the overall market in 2011. The region is expected to witness a remarkable growth rate due to a growing awareness about healthcare issues.

Asia Pacific is also anticipated to be an emerging region in the global medical disposables market due to a large pool of patients, rising expenditure on healthcare, and improving disposable incomes.

The high prevalence of diseases, growing pool of geriatrics, and increasing demand for healthcare are all contributing towards the growth of the global medical disposables market. Analysts predict that growing volumes of patient admissions and the need for diagnostics will continue to propel the demand for medical disposables in the coming years. However, tough approval norms set by FDA and GMP are expected to restrain the market in the forecast years, predict analysts.

Predictions for Hemoglobin A1c Testing Devices Market in the next decade

Testing the levels of glycated hemoglobin provides an assurance to the healthcare practitioner about the patient’s blood glucose level. This test can be used for diagnosis and monitoring of hemoglobin A1c levels in diabetic patients. Since A1C test reflects the average amount of glucose for the past 2 to 3 months, it is opined to be more reliable than conventional blood glucose test. Physicians are increasingly prescribing HbA1c test to their patients which will lead to an increase in the test volume. Moreover, rising diabetes incidence rate is a major driver for the HbA1c testing market. With growing awareness about prevention and management of diabetes, the demand for HbA1c testing devices will rise rapidly especially in the Asia-Pacific, Latin America, MiddleEast and African regions.

Moreover, advent of these devices for the diagnosis of diabetes will further bolster the demand for these devices in future. For instance, approval for the COBAS INTEGRA 800 Tina-quant HbA1cDx assay, in 2013and Abbott’s ARCHITECT Clinical Chemistry Hemoglobin A1c (HbA1c) test approved in 2014 for the diagnosis of diabetes were the major steps in the hemoglobin A1c testing industry. With this diagnostic tools, physicians can combat the rising incidence of diabetes with timely and appropriate actions in identifying and managing diabetes.

Based on the end-use, the global hemoglobin A1c testing devices market is categorized into two segments namely laboratory testing and point-of-care (POC) testing devices. Laboratory testing devices held the majority share of the market in 2012, while the global market for point-of-care testing devices is expected to grow at a faster paceduring the forecast period.

Based on technologies, the hemoglobin A1c testing devices market is further categorized into five segments, namely, ion-exchange HPLC, immunoassay, boronate affinity chromatography, direct enzymatic assay and others. The boronate affinity chromatography market will be growing at a faster pace during the forecast period as this technology has no interference from hemoglobin variants and is also used in both laboratory as well as point-of-care testing. Healthcare practitioners are recommending the use of devices which offer least variant interference and this would elevate the demand for boronate affinity chromatography in HbA1c testing.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1620

Geographically, the global hemoglobin A1c testing devices market is categorized into four regions, North America, Europe, Asia-Pacific and Rest of the World (RoW). North America was the market leader in 2012 due to high patient awareness coupled with the presence of sophisticated healthcare infrastructure. Also, the adoption of automated processes is rapid in this region which results in high demand for advanced laboratory and point-of-care testing devices with new technologies. Conversely, the Asia-Pacific region is expected to grow at a higher CAGR than others, owing to the presence of unmet healthcare needs, large diabetic population and increase in healthcare expenditure. Moreover, rising diabetes awareness among the general population will generate demand for diagnostic devices for HbA1c testing. Also, inadequate accessibility to the clinical laboratories in this region, demands more of point-of-care devices to enable immediate results during the patient visit.

The global hemoglobin A1c testing devices market is characterized by the presence of some of the major companies including Abbott Laboratories, Alere, Inc., Arkray, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Siemens Healthcare and Trinity Biotech plc. These players are seeking to develop HbA1c analyzers with quicker turnaround time, higher accuracy and reliable results. Moreover, approval of devices for diagnosis of diabetes has reinforced the development activities of these organizations to introduce products for rapid and early diagnosis.

Microfluidic Device Systems Market in North America to Grow at Striking 21.70% CAGR from 2013 to 2019

There has been a recent release of a new report on the global microfluidic device systems market by Transparency Market Research (TMR). The report suggests that the global microfluidic device market is estimated to grow at a CAGR of 22.8% during the period of 2013 to 2019. The market, which was valued at US$1.5 bn in 2013, will reach US$5.2 bn in 2019.The report, which is titled “Microfluidic Device System Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019,” provides a comprehensive study on the analysis of the microfluidic device market for the period from 2014 to 2019, wherein 2013 is considered as the base year for calculation. The report contains data related to the current market dynamics, trends, market drivers, restraints, and also the strategic developments propelling the global microfluidic device systems market.

The report states that the rising demand for microfluidic devices in proteomics and genomics, point of care testing, and miniaturization of chips are the chief driving forces behind the microfluidic device systems market’s growth. Another factor that could fuel the growth of the microfluidic device systems market is a change in the material mix, which would provide an opportunity to new market entrants. Conversely, strict regulations and standards for global affiliation of medical devices as well as high performance and consistency in quality of the devices are some of the factors limiting the growth of the microfluidic device systems market. Manufacturing issues such as surface chemistry and geometrical issues also account for the challenges faced by the microfluidic device systems market.

The report categorizes the global market for microfluidic device systems chiefly on the basis of four criteria: geography, industry, application, and materials used in the manufacturing process of microfluidic devices.

On the basis of application, the market for microfluidic devices is segmented into pharmaceutical and life sciences research, point of care testing, environment and industrial, clinical and veterinary diagnostics, and drug delivery. Of these, the largest segment of the microfluidic devices market is the veterinary and clinical diagnostic application segment.

Request free Sample pages of premium Research Report : http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1561

Geographically, the microfluidic devices market is segmented into Asia, North America and Europe, wherein North America dominates the global microfluidic devices market, while Asia is a rapidly developing region for the microfluidic devices market.

On the basis of industry, the microfluidic devices market is segmented into in- vitro diagnostics, pharmaceuticals, and medical devices. Among these, in-vitro diagnostics is the largest industry and is estimated to reach US$3.3 bn in 2019.

The report profiles some of the prominent companies such as Abbott Laboratories, Roche Diagnostics, Siemens Healthcare, Becton Dickinson and Company, Agilent Technologies, Fluidigm Corporation, Bio-Rad Laboratories, and Johnson & Johnson, which are key players in the microfluidic devices market.

The market for microfluidics devices can be expected to rise as microfluidics is an evolving field with a huge potential commercially. With applications in various fields such as cell biology research, protein crystallization, and medicine, microfluidics will remain in the market due to its efficacy in the field of treatment.

Medical Disposables Market: Industry Players Shifting Focus towards Developing Economies

A new market research report has been recently published by Transparency Market Research, titled “Medical Disposables Market - Global and U.S. Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018”. According to the research study, in 2011, the global medical disposables market was worth US$144.6 bn and is anticipated to be worth US$193.9 bn by the end of 2018, growing significantly at a 4.30% CAGR between 2012 and 2018.

The research report has provided a detailed analysis of the global medical disposables market, emphasizing on the U.S. market. The report further talks about the market overview, product segmentation, growth drivers, restrains, and vendor analysis. The 50-page research report makes use of graphical representation such as tables and charts to showcase historical data and forecast figures.

Rising demand for healthcare due to the rising global aging population, rising prevalence of chronic conditions that need long-time therapies, and expanding volume of inpatient days and hospital admissions are some of the major factors boosting the demand for medical disposables in the coming years. On the other hand, rigid FDA and GMP approval norms and reduction in the prevalence of healthcare-associated infections are the factors that are expected to curb the growth of this market in the forecast period.

On the basis of product, the global medical disposables market has been segmented into nonwoven medical disposables, wound management disposables, drug delivery disposables, and others (such as laboratory and diagnostic disposables). Furthermore, the market has been classified on the basis of end use into home healthcare facilities, outpatient facilities, emergency care, hospitals, and physician offices. Among these, the hospitals segment is at the forefront of the U.S. medical disposables market. The demand for medical disposables is anticipated to rise in hospitals, thanks to the rising number of patient admissions, surgical procedures, and emergency visits.

Interpret a Competitive outlook Analysis Report with free PDF Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=388

The global medical disposables market has been further segmented on the basis of geography into North America, Asia Pacific, Europe, and Rest of the World. Among all these regions, North America exhibited strong demand for all product segments of the market in the recent years. According to the report, the U.S. medical disposables market held around 70% of the North America medical disposables market. In 2011, North America accounted for the largest share of 35% in the global medical disposables market. On the other hand, Asia Pacific is expected to witness rapid growth owing to rising awareness for healthcare. Some of the other factors that are expected to boost the demand for medical disposables in the Asia Pacific market are the huge aging population, increasing disposable income, and rising expenditure by governments on healthcare. The substantial rise of developing nations such as China and India is anticipated to propel the Asia Pacific medical disposables market.

The report also talks about the prominent companies that are operating in the global medical disposables market. The comprehensive analysis includes company overview, product portfolio, business strategies, financial overview, SWOT analysis, and recent developments. Some of the key players are Dickinson, and Company, 3M Company, Becton, Johnson & Johnson, and Covidien plc.

Neuromodulation Devices Market: Technical Expertise, Quality, Reliability and Timeliness

The neuromodulation devices market is oligopolistic in nature with the top four companies representing nearly 91% of the overall market, finds Transparency Market Research (TMR) in a new study. The key players in the global neuromodulation devices market are Boston Scientific, Cyberonics, Medtronic, and St. Judes Medical.

There are high entry barriers for new players owing to high capital investment and stringent government regulations. “However, large companies can enter the neuromodulation devices market through mergers and by acquiring smaller companies,” says the author of the report. The most lucrative way for new vendors to enter the global neuromodulation devices market is through the ownership of groundbreaking and innovative technologies, as technological advancement is a major driving force for the market.

The neuromodulation devices market is oligopolistic in nature with the top four companies representing nearly 91% of the overall market, finds Transparency Market Research (TMR) in a new study. The key players in the global neuromodulation devices market are Boston Scientific, Cyberonics, Medtronic, and St. Judes Medical.

There are high entry barriers for new players owing to high capital investment and stringent government regulations. “However, large companies can enter the neuromodulation devices market through mergers and by acquiring smaller companies,” says the author of the report. The most lucrative way for new vendors to enter the global neuromodulation devices market is through the ownership of groundbreaking and innovative technologies, as technological advancement is a major driving force for the market.

External Funding for Clinical Studies to Augur Well for Sales of Neuromodulation Devices

The rising geriatric population, especially in developed countries such as the U.S., Japan, and Germany are likely to produce notable growth opportunities for the global neuromodulation devices market. This is because of the fact that the aged people are more susceptible to neurological disorders such as Parkinson’s and Alzheimer’s. Neuromodulation devices have proven to be extremely effective in treating Parkinson’s and other chronic illnesses induced by old age.

The growth of the global neuromodulation devices market is backed by external funding to conduct clinical studies. Such initiatives pave the way for the development of technologically updated devices and also reduce the R&D costs pertaining to the development of new products.

Moreover, a rise in the prevalence of chronic diseases common in all age groups, such as migraine and epilepsy has fuelled the demand for neuromodulation devices. “Some of the neurological disorders such as migraine have unmet medical needs, which gives a further push to the growth of the global neuromodulation devices market,” says a TMR analyst.

The minimally invasive characteristic of neuromodulation devices has helped the global neuromodulation devices market tread along a promising growth path. The increasing demand for minimally invasive surgeries can be attributed to fast recovery time and scar-less treatment.

Some other factors playing a crucial role in the growth of the global neuromodulation devices market are increasing healthcare related consumer expenditure, add-on therapy nature of neuromodulation devices, and technological advancements that ensure promising treatment options.

Side effects Associated with Neuromodulation Devices to Discourage Adoption Amongst Patients

Neuromodulation devices are planted through a surgery, which can have side effects on the body such as allergy or hoarseness. Neuromodulation devices also carry the risk of damaging the surrounding nerves and blood vessels owing to the electrical impulses generated by them. These factors tend to withdraw the interest of the patients in the neuromodulation devices implantation, thereby impeding the growth of the global neuromodulation devices market. In such a case, the availability of alternate treatment procedures such as drugs and other surgeries (e.g. Pallidotomy) hampers the growth of the global neuromodulation devices market.

The neuromodulation devices have to undergo several rigorous clinical trials prior to their approval and availability in the market. This procedure increases the development cost of neuromodulation devices and challenges the vendors operating in the global neuromodulation devices market, thereby discouraging the growth of the market. Also, the rapidly changing technologies pose a threat to the growth of the market. This trend makes the market volatile and acts as a high impact restraining factor for the market as technologies get outdated and redundant at a great pace.

However, the increasing instances of outsourcing the manufacturing of neuromodulation devices are likely to curtail development costs while focusing on the development of safer technologies.

North America Market Shares to Show Downward Slide Owing to Lag in FDA Approval Process

The global neuromodulation devices market was valued at US$3.155 bn in 2012 and is anticipated to rise to US$7.072 bn in 2018, progressing at a CAGR of 14.4% from 2013 to 2018. In terms of geography, North America was the leading segment by revenue in 2013 and is anticipated to lead the market by the end of 2018 with a dominant share of 60% in the global neuromodulation devices market. However, the regional segment is expected to lose its share due to the strict government regulations mandated in the U.S. and the delays in FDA approval process.

View exclusive Global strategic Business report : http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=627

These factors will compel vendors to shift their focus to more conducive markets in the Asia Pacific and European regions. The APAC region will be a promising area of growth in the global neuromodulation devices market.

Based on technology, spinal cord stimulation devices was the leading segment by revenue in 2013 and is expected to retain its leadership till 2018. However, sacral nerve stimulation devices will register the fastest growth owing to growing prevalence of urinary incontinence.

The information presented in this review is based on a Transparency Market Research report, titled, ‘Neuromodulation Devices Market - Global Industry Size, Market Share, Trends, Analysis, and Forecast 2012 - 2018.’

Life Science Reagents Market to Reach US$25.7 bn by 2020 owing to Rising Activities of R&D within the Field of Pharmaceuticals

Life science reagents include reagents that are used in biotechnology, bioscience and pharmaceutical industries. Since the last decade, the global life science reagents market has experienced impressive growth due to factors such as technology advancement and expansion in applications of biotechnology and biosciences in the field of healthcare and pharmaceuticals. Some other factors contributing to the growth of the life science reagents market include increasing disease prevalence and rise in their mortality rates, aging of population and increased research and development activities in the field of biosciences, biotechnology and pharmaceuticals. Based on the commercially available life science reagent products, the global life science reagents market is categorized as PCR reagent kits, cell and tissue culture reagents, flow cytometry reagents, electrophoresis reagents, chromatography reagents, in-vitro diagnostic reagents and others. In addition, the global life science reagents market is segmented on the basis of end users, namely, commercial and contract manufacturers, research and academics, clinical laboratories, and forensic laboratories.

Chromatography reagents are the most widely used reagent products thus, capturing the highest market share in the overall life science reagents market. Wide use of chromatography in almost every aspect of biotechnology-related research and product development is the prime contributing factor for the dominance of this segment. On the other hand, the market share of electrophoresis reagents is the lowest as compared to other products available in the overall life science reagents market. Technological advancement and increasing initiatives towards the expansion of scope of biotechnology and life science has led to perpetual rise in demand for life science reagents worldwide.

In terms of end users, research and academic institutions are the largest consumers of life science reagents. Technological development and corresponding rise in the number of available skilled labor in emerging economies have widened the scope for research outsourcing in the developing markets of India and Brazil. Processes such as pharmaceutical contract manufacturing and cosmetic product manufacturing constitute the largest commercial consumers of life science reagents. Due to the requirement of high capital investment to perform stability studies, formulation development and phase-I trials, several pharmaceutical companies outsource drug development operations to contract manufacturing companies to focus on their core activities of manufacturing drugs and marketing, thereby controlling the in-house budget.

Get a Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1162

The global life science reagents market is fragmented in terms of presence of a large number of multinational and local players. The mature market players such as Sigma Aldrich, Abbott Laboratories, Life Technologies, Bio-Rad and others currently dominate this market with their patent protected products and intensive growth strategies of acquiring new market entrants providing breakthrough technologies. In addition, large patent repositories of the established market players restrains the entry and growth of new players in the life science reagents market.

Geographically, North America dominates the global life science reagents market and is followed by Europe. Asia-Pacific is expected to show the highest growth rate owing to factors such as increasing research and development activities, rise in the number of government aids, business clusters and trade conglomerates to strengthen biotechnology industry in the respective national markets and rise in the availability of skilled manpower at cheaper cost, thereby increasing the scope for outsourcing of biotech projects. New trend of outsourcing research activities in Asia-Pacific is one of the major driving forces for the growth of the life science reagents market in this region. Countries such as Brazil, Mexico and Argentina in the Rest of the World (RoW) region are adopting strategies such as formation of biotechnology clusters and attracting foreign investments to boost the domestic biotechnology industry. However, stringent regulatory rules restrain the entry of new products in the market and thus, restrict the growth of life science reagents market in these countries.

Electric Handheld BP Devices Market Trends & Forecast up to 2019

Transparency Market Research, a leading provider of the latest market intelligence, has compiled a vast array of data on the medical devices industry over the years. The most recent research effort has been conducted under the title “Electric Handheld BP Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019.” All factors that are influencing the global electrical handheld BP devices market have been incorporated in this study.

According to the World Health Organization, in 2008, almost a billion people around the world were suffering from uncontrolled blood pressure issues. This had emerged as a major growth force for the global electrical handheld BP devices market, especially in the technological developments department. As it stands, there is a major need across the world for medical devices that are portable, easy to use, and minimally invasive.

One of the greatest drivers of the global electrical handheld BP devices market currently is the high prevalence of chronic diseases across the world. Blood pressure is one of the most common vitals that need to be regularly checked for patients of chronic diseases and therefore, the global electrical handheld BP devices market is expected to exhibit a high growth rate. Its growth rate will be directly proportional to the number of diagnoses of chronic diseases.

Other drivers of the global electrical handheld BP devices market include the increasing rate of awareness among patients regarding the modern devices available in this market and the various technological developments and innovations. One of the greater innovations is a reduction in the size of several electronic devices, which is making it possible for patients to easily carry the devices around.

Get a Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1606

The leading region in terms of consumption as well as research and development efforts in the global electrical handheld BP devices market has been North America. This region is followed by Europe and then Asia Pacific, which is presenting rapid growth. The growth of Asia Pacific can be attributed to the high population density and the growing diagnosis rates of chronic disorders. One of the greatest market opportunities is being presented by the Latin America electrical handheld BP devices market owing to major steps taken by Brazil and Mexico in the healthcare industry.

The list of key players in the global electrical handheld BP devices market includes A & D Medical, Microlife, Mabis Healthcare, Inc., Medisana AG, Braun GmbH, American Diagnostic Corp, Welch Allyn, Omron Healthcare Co., Ltd., and Philips Healthcare.

Predictions for Hemoglobin A1c Testing Devices Market in the next decade

The global hemoglobin A1c testing devices market will expand at a CAGR of 10.3% from 2013 to 2019. This market was valued at US$0.94 bn in 2012 and owing to its current and expected drivers, will reach US$1.86 bn by the end of 2019.The latest data on the global hemoglobin A1c testing devices market is maintained in a research report released by Transparency Market Research, titled “Hemoglobin A1c Testing Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019.”

A1c is a common blood test used in many healthcare organizations in order to test a patient for diabetes, both type 1 and type 2. The test is also used to measure the level to which the patient is coping with the disease. Other common names for the A1c test include the HbA1c test, the glycosylated hemoglobin test, and glycated hemoglobin test.

According to the report, the global hemoglobin A1c testing devices market is currently being driven by a large growth in patient demand. This can be attributed to the increase in the percentage of the geriatric demographic, as well as the growing prevalence of diabetes across the world.

In calculating the overall growth rate and future scope of the global hemoglobin A1c testing devices market, the report also takes into consideration the various factors that are – and might continue to – hinder the market growth. Of these, the biggest hurdle faced by the market is the high cost of these devices. Owing to this high cost, the total number of patients with access to A1c testing is lower, thereby creating a downturn in the overall development rate of the market.

The report provides a segmented analysis of the global hemoglobin A1c testing devices market, based on the categories of end users, technologies, and geography.

On the basis of end use, the global hemoglobin A1c testing devices market is bifurcated into PoC testing devices and laboratory testing devices. Of these, the market is currently led by the latter segment. The laboratory testing devices segment had also dominated the market in 2012, with a share of over 66% in the market. It will continue to dominate the global hemoglobin A1c testing devices market till 2019, but will show a far slower growth rate as compared to the point-of-contact testing devices segment.

Get a Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1620

In terms of technology, the global hemoglobin A1c testing devices market was led by the ion-exchange HPCL segment. The report, however, puts the segment of boronate affinity chromatography at the top of the technologies to be used in the market in 2019 based on its rapid growth rate.

The report’s geographical analysis of the global hemoglobin A1c testing devices market reveals North America to be the leading region in the market in 2012. The report also expects this region to maintain its leading position in the market till the end of the forecast period. At the same time, the region with the fastest growth rate is said to be Asia Pacific owing to its rapidly developing healthcare industry and the high population density, coupled with a rising number of diabetes prevalence.

The key companies in the global hemoglobin A1c testing devices market are Trinity Biotech, Siemens Healthcare, F. Hoffmann-La Roche Ltd., Menarini, EKF Diagnostics Holdings plc, Chek Diagnostics, Danaher Corp., Bio-Rad Laboratories Inc., Alere Inc., ARKRAY Inc., and Abbott Laboratories.

Global Microfluidic Device System Market to be Driven by Surging Demand from Proteomics and Genomics

Drug screening, micro fuel cells, chemical micro reactor, sugar testers, and microprocessor cooling are a few of the key areas which extensively use microfluidic devices. In 2013, the global microfluidic device system market had a market value of US$1531.2 million. Owing to factors such as increasing application of microfluidic device systems in the areas of proteomics and genomics, this market is anticipated to reach US$5246.4 million by 2019, growing at a CAGR of 22.8% from 2013 to 2019. Microfluidic devices are a nascent scientific field of study with enormous commercial and analytical applications.

The robust growth of the global microfluidic device system market can be attributed to key factors such as a high demand for point of care testing, miniaturization of chips, and changes in material mix. Miniaturization of chips leads to lower costs of testing, and changing material mix leads to newer opportunities for new market entrants.

Demand for Point of Care Testing to Propel Overall Demand from Microfluidics Device System Market

The global microfluidic device system market is segmented on the basis of material type, application, industry, and geography. On the basis of material type, this market is segmented into polymer, silicon, and glass. Based on application, the global microfluidic device system market is classified into environment and industry, clinical and veterinary diagnostics, drug delivery, point of care testing, analytical devices, and pharmaceutical and life science research. Within the application segment, clinical and veterinary diagnostics leads the overall microfluidic device system market.

Microfluidic device systems are also applied in the areas of protein crystallization, cell biology research, and medicine. Latest healthcare trends, which include home healthcare, reveal that point of care testing is a highly sought-after delivery method for healthcare services. In the area of genomics, microfluidic device systems ensure higher test speed, lower consumption of reagents, and greater efficacy.

On the basis of industry, the microfluidic device system market is segmented into medical devices, in-vitro diagnostics, and pharmaceuticals. The in-vitro diagnostics segment holds the largest share within the industry segmentation of the global microfluidic device system market.

Asia to Lead Microfluidics Device System Market Due to Growing Spread of Healthcare Infrastructure

Geographically, the global microfluidic device system market is segmented into Asia, North America, Europe, and Rest of the World. North America leads the overall microfluidic device system market in terms of both revenue and volume. Some of the prominent market drivers for the North America microfluidic device system market include greater technological development, high incidence of lifestyle diseases, a rapidly growing geriatric population, and greater health awareness.

In 2013, this regional market was worth US$644.5 million and is anticipated to report a value of US$2095.5 million by 2019. The Asia microfluidic device system market is expanding rapidly owing to significant growth of the industry and application segments of medical devices and point of care testing, respectively.

Download Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1561

Reduced Side Effects and Higher Efficacy Drives Demand for Microfluidic Device Systems

Microfluidics technology ensures greater efficacy of treatments and reduction of side effects. High demand for miniaturization of pharma and medical devices is a prominent factor that drives the demand for microfluidics technology. Ongoing trends also indicate that this technology is increasingly being applied in the area of micro engineering solutions.

Growing at a 23.2% CAGR, the in-vitro diagnostics segment is anticipated to reach a market value of US$3317.4 million by 2019 from US$949.6 million in 2013.

The overall microfluidic device system market is characterized by a number of product innovations and partnerships between major market players. Some of the key factors that hamper the growth of the global microfluidic device system market are strict regulatory standards and issues pertaining to geometrical and surface chemistry.

The key companies operating in the microfluidic device system market are Becton, Dickinson and Company, Johnson & Johnson, Micronit Microfluidics, Dolomite Centre, RainDance Technologies, Bio-Rad Laboratories, Agilent Technologies Inc., Abbott Laboratories, and Roche Diagnostics.

Hyaluronic Acid Market to Register Impressive CAGR, Driven by Increasing Demand for Anti-Aging Procedures

Hyaluronic acid is a crucial part of the human skin and has a beneficial effect on the durability of skin. It is also called hyaluronan or hyaluronate and is naturally present in connective, neural, and epithelial tissues. The production of hyaluronic acid slows down with aging, aiding the degradation of skin cells. The rising awareness about this natural process has led to high demand for hyaluronic acid products of various types. According to Transparency Market Research, the global hyaluronic acid products market is expected to rise to a valuation of US$9.8 bn by 2019.

Here are the primary driving factors propelling the global hyaluronic acid products market:

Increasing Demand for Anti-aging Products: The global population is keener than ever to maintain a youthful appearance, leading to steady demand for various skincare products. The rising usage of hyaluronic acid, due to its biocompatibility, has resulted in high demand from the global hyaluronic acid products market.

Rising Awareness Regarding Risks of Synthetic Skincare Products: The USP of hyaluronic acid has always been the fact that it is not only naturally found but also naturally produced within the human body. This renders it safe for skincare applications. Since most artificial skincare compounds can have adverse effects on the skin, the usage of hyaluronic acid products is on the rise, boosting the global market.

High Demand for Minimally Invasive Procedures: The convenience of hyaluronic acid products, which are just as effective when applied topically as when injected into the body, is another major factor propelling the global hyaluronic acid products market. Instead of injections of compounds boosting the appearance of skin, such as botox, the usage of hyaluronic acid products to boost the internal system maintaining the health of skin is rising.

Request for Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2033

Rising Living Standards in Asia Pacific to Boost Global Hyaluronic Acid Products Market

The regional market for hyaluronic acid products in Asia Pacific was the third largest regional segment of the global hyaluronic acid products market. This region, however, is expected to be the fastest growing market for hyaluronic acid products in the coming years. Along with other developing countries in Rest of the World, Asia Pacific countries are expected to witness high rates of development of medical infrastructure in the coming years. This will directly propel the global hyaluronic acid products market, as treatments involving hyaluronic acid products will be more accessible to the common man.

In addition to this, the rising living standards in dynamic countries such as India, China, Thailand, Singapore, etc. will also benefit the hyaluronic acid products market. The increasing awareness about and demand for maintaining a youthful appearance as a result of the increased living standards will propel the Asia Pacific hyaluronic acid products market at a steady pace in the coming years.

Hemoglobin A1c Testing Devices Market in the next decade

Testing the levels of glycated hemoglobin provides an assurance to the healthcare practitioner about the patient’s blood glucose level. This test can be used for diagnosis and monitoring of hemoglobin A1c levels in diabetic patients. Since A1C test reflects the average amount of glucose for the past 2 to 3 months, it is opined to be more reliable than conventional blood glucose test. Physicians are increasingly prescribing HbA1c test to their patients which will lead to an increase in the test volume. Moreover, rising diabetes incidence rate is a major driver for the HbA1c testing market. With growing awareness about prevention and management of diabetes, the demand for HbA1c testing devices will rise rapidly especially in the Asia-Pacific, Latin America, MiddleEast and African regions.

Moreover, advent of these devices for the diagnosis of diabetes will further bolster the demand for these devices in future. For instance, approval for the COBAS INTEGRA 800 Tina-quant HbA1cDx assay, in 2013and Abbott’s ARCHITECT Clinical Chemistry Hemoglobin A1c (HbA1c) test approved in 2014 for the diagnosis of diabetes were the major steps in the hemoglobin A1c testing industry. With this diagnostic tools, physicians can combat the rising incidence of diabetes with timely and appropriate actions in identifying and managing diabetes.

Based on the end-use, the global hemoglobin A1c testing devices market is categorized into two segments namely laboratory testing and point-of-care (POC) testing devices. Laboratory testing devices held the majority share of the market in 2012, while the global market for point-of-care testing devices is expected to grow at a faster paceduring the forecast period.

Based on technologies, the hemoglobin A1c testing devices market is further categorized into five segments, namely, ion-exchange HPLC, immunoassay, boronate affinity chromatography, direct enzymatic assay and others. The boronate affinity chromatography market will be growing at a faster pace during the forecast period as this technology has no interference from hemoglobin variants and is also used in both laboratory as well as point-of-care testing. Healthcare practitioners are recommending the use of devices which offer least variant interference and this would elevate the demand for boronate affinity chromatography in HbA1c testing.

Geographically, the global hemoglobin A1c testing devices market is categorized into four regions, North America, Europe, Asia-Pacific and Rest of the World (RoW). North America was the market leader in 2012 due to high patient awareness coupled with the presence of sophisticated healthcare infrastructure. Also, the adoption of automated processes is rapid in this region which results in high demand for advanced laboratory and point-of-care testing devices with new technologies. Conversely, the Asia-Pacific region is expected to grow at a higher CAGR than others, owing to the presence of unmet healthcare needs, large diabetic population and increase in healthcare expenditure. Moreover, rising diabetes awareness among the general population will generate demand for diagnostic devices for HbA1c testing. Also, inadequate accessibility to the clinical laboratories in this region, demands more of point-of-care devices to enable immediate results during the patient visit.

Request A Sample Of This Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1620

The global hemoglobin A1c testing devices market is characterized by the presence of some of the major companies including Abbott Laboratories, Alere, Inc., Arkray, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Siemens Healthcare and Trinity Biotech plc. These players are seeking to develop HbA1c analyzers with quicker turnaround time, higher accuracy and reliable results. Moreover, approval of devices for diagnosis of diabetes has reinforced the development activities of these organizations to introduce products for rapid and early diagnosis.

Teleradiology Market Responds to Impressive Progress in Medicine and Healthcare

Transparency Market Research has published a new report on the global teleradiology market. As per the report, the global teleradiology market is predicted to expand at a 22.30% CAGR during the period between 2013 and 2019. The report, titled ‘Teleradiology Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019,’ states that the global teleradiology market stood at US$0.9 bn in 2012 and is expected to reach US$3.8 bn by 2019 owing to factors such as technological advancements and the introduction of mhealth services.

Teleradiology consists of the electronic transmission of radiological images from a particular location to another in a digital format using the internet. Image transfer is primarily carried out from the sender’s end to a secondary location for either consultation or an official diagnosis. Consistent developments and advancements in digital imaging technology have favored the acceptance of teleradiology technologies. The increasing acceptance of social media platforms and the internet in general is further expected to augment the use of teleradiology practices across the globe.

Continuous upgradation of radiology information systems (RIS) and picture archiving and communication systems (PACS) is expected to enhance the teleradiology process. The global teleradiology market is segmented on the basis of geography and modality. Based on modality, the global teleradiology market is classified into x-ray, ultrasound, computed tomography (CT), nuclear imaging, and magnetic resonance imaging (MRI). The x-ray teleradiology segment is expected to register new growth opportunities due to increased awareness, low costs compared to other modalities, and increasing digitalization.

Ultrasound imaging technology, popularly used in diagnosing women’s ailments, is majorly employed to track and visualize development stages of a fetus at the time of pregnancy. Compared with x-rays, ultrasound imaging technology is more beneficial due to its minimally invasive nature. The acceptance of MRI imaging technology is still at a nascent stage due to the high costs of the equipment and lack of technical expertise.

Based on geography, the global teleradiology market is divided into Europe, Asia Pacific, North America, and Rest of the World. In 2012, the global teleradiology market was led by North America, which held a revenue share of more than 33%. The presence of well-equipped healthcare institutions and hospitals and the increasing use of high-bandwidth internet are predicted to propel the North America teleradiology market in the years to come.

Brochure Download: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1132

The Asia Pacific teleradiology market is expected to register considerable growth in the coming few years due to ongoing developments in healthcare informatics and medical imaging platforms. However, lack of image data security is expected to hamper the growth of the global teleradiology market through the forecast period.

Agfa-Gevaert N.V., American TeleCare, Inc., Cybernet Systems Corporation, ONRAD, Inc., Radisphere National Radiology Group, Inc., Sectra AB, StatRad, Teleradiology Solutions, and Virtual Radiologic (vRad) are some of the leading companies in the global teleradiology market. The entry of new companies is expected to make the global teleradiology market highly competitive in the coming years.